6TH JOINT MEETING ON LUNG CANCER

INNOVATIVE

DRUG MOLECULES & PREDICTIVE BIOMARKERS

14 - 15 OCTOBER 2027 • NICE, FRANCE



RespirERA
IHU Côte d'Azur

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center

Programme

14 October

8:00 **Welcome coffee | Booth exhibition**

8:30 **Welcome & Opening Remarks**
Solange PETERS, John V. HEYMACH, Ignacio WISTUBA, Sandurai A. MANI, Mihaela ALDEA, Albrecht STENZINGER, Paul HOFMAN, Umberto MALAPELLE

Session 1 : John V. HEYMACH

9:00 **Immunotherapy for Non-AGA Early NSCLC: Opportunities and Challenges**
Solange PETERS | CHU vaudois, Lausanne, Switzerland

9:30 **Update on Therapeutic Advances in ADCs for Lung Cancer**
David PLANCHARD | Gustave Roussy Institute, Villejuif, France

10:00 **Minimal Residual Disease in Non-Small Cell Lung Cancer**
Christian ROLFO | The Ohio State University Wexner Medical Center, Colombus, USA

10:30 **Coffee break | Booth exhibition**

11:00 **Precision Treatment of Brain Metastases in Lung Cancer: Progress and Unmet Needs**
Ernest NADAL | Catalan Institute of Oncology, Barcelona, Spain

11:30 **Leveraging novel combinations and cytokines to overcome IO resistance in NSCLC**
Natalie VOKES | MD Anderson Cancer Center, Houston, USA

12:00 **RNA-signatures in NSCLC and their implications on response prediction**
Albrecht STENZINGER | Heidelberg University, Heidelberg, Germany

12:30 **Lunch break**

Session 2 : Albrecht STENZINGER

1:30 **Reprogramming neutrophils to overcome immunotherapy resistance**
Jean ALBRANQUES | RespirERA Institute, Nice, France

2:00 **Asymmetric Cell Division and the Biology of Cancer Adaptation**
Sandurai A. MANI | Brown University, Providence, USA

2:30 **Transforming Lung Cancer Diagnostics: A Strategic Blueprint for multi-modal DNA, RNA, Spatial Transcriptomics, and Long-Read Sequencing.**
Shashikant KULKARNI | MD Anderson Cancer Center, Houston, USA

3:00 **Coffee break | Booth exhibition**

3:30 **An integrative pathology strategy to characterize KRAS-mutant NSCLC and guide precision therapies**
Guylène RIGNOL | RespirERA Institute, Nice, France

4:00 **Mechanisms of response and tolerance to RAS inhibition in NSCLC**
Ferdinandos SKOULIDIS | MD Anderson Cancer Center, Houston, USA

Programme

15 October

9:00 **Welcome coffee | Booth exhibition**

Session 3 : Mihaela ALDEA

9:30 **Redefining Biomarkers in NSCLC Through Computational Pathology and Artificial Intelligence**
Nicola FUSCO | European Institute of Oncology, Milan, Italy

10:00 **Multimodal Biomarker Extraction for Lung Cancer Targeted Therapy**
Hervé DELINGETTE | RespirERA Institute, Nice, France

10:30 **Digital Twins for Lung Cancer: Integrating Imaging, Molecular Data, and AI**
Jia WU | MD Anderson Cancer Center, Houston, USA

11:00 **Coffee break | Booth exhibition**

11:30 **Digital and Computational Pathology in Lung Cancer Diagnosis**
Ignacio WISTUBA | Moffitt Cancer Center, Tempa, USA

12:00 **MMAI Approach in Precision Oncology. Where do we stand at the IHU RespirERA ?**
Paul HOFMAN | RespirERA Institute, Nice, France

12:30 **3D Biology in Liquid Biopsy**
Umberto MALAPELLE | University of Naples Federico II, Naples, Italy

1:00 **Lunch break**

Session 4 : Solange PETERS

2:00 **MTAP-Deleted Lung Cancer: Bridging Today's Evidence and Tomorrow's Biomarker Gaps**
Mihaela ALDEA | Gustave Roussy Institute, Villejuif, France

2:30 **Targeting the residual disease in patients with advanced lung cancer harboring oncogenic addiction**
Julien MAZIERES | IUCT Oncopole, Toulouse, France

3:00 **Differences and similarities among EGFR classical, PACC and exon20 mutations in lung cancer**
Xiuning LE | MD Anderson Cancer Center, Houston, USA

3:30 **The molecular determinants of HER2 TKI selectivity and therapeutic resistance in NSCLC**
John V. HEYMACH | MD Anderson Cancer Center, Houston, USA

4:00 **Acknowledgement & Closing Remarks**
Solange PETERS, John V. HEYMACH, Ignacio WISTUBA, Sandurai A. MANI, Mihaela ALDEA, Albrecht STENZINGER, Paul HOFMAN

Speakers

International experts in innovative drug molecules, predictive biomarkers and precision medicine in lung cancer.



Jean ALBRENGUES
RespirERA Institute
Nice, France



Mihaela ALDEA
Gustave Roussy Institute
Villejuif, France



Hervé DELINGETTE
RespirERA Institute
Nice, France



Nicola FUSCO
European Institute of Oncology
Milan, Italy



John V. HEYMACH
MD Anderson Cancer Center
Houston, USA



Paul HOFMAN
RespirERA Institute
Nice, France



Shashikant KULKARNI
MD Anderson Cancer Center
Houston, USA



Xiuning LE
MD Anderson Cancer Center
Houston, USA



Ulberto MALAPELLE
University of Naples Federico II
Naples, Italy



Sandurai A. MANI
Brown University
Providence, USA



Julien MAZIERES
IUCT Oncopole
Toulouse, France



Ernest NADAL
Catalan Institute of Oncology
Barcelona, Spain



Solange PETERS
CHU vaudois
Lausanne, Switzerland



David PLANCHARD
Gustave Roussy Institute
Villejuif, France



Guylène RIGNOL
RespirERA Institute
Nice, France



Christian ROLFO
The Ohio State University
Wexner Medical Center
Colombus, USA



Ferdinandos SKOULIDIS
MD Anderson Cancer Center
Houston, USA



Albrecht STENZINGER
Heidelberg University
Heidelberg, Germany



Natalie VOKES
MD Anderson Cancer Center
Houston, USA



Ignacio WISTUBA
Moffitt Cancer Center
Tempa, USA



Jia WU
MD Anderson Cancer Center
Houston, USA

Supported by the ANR through France 2030: ANR-23-IAHU-0007